4//SEC Filing
Stehman-Breen Catherine 4
Accession 0000899243-20-026179
CIK 0001818794other
Filed
Sep 22, 8:00 PM ET
Accepted
Sep 23, 7:03 PM ET
Size
14.2 KB
Accession
0000899243-20-026179
Insider Transaction Report
Form 4
Stehman-Breen Catherine
Director
Transactions
- Conversion
Series B Preferred Stock
2020-09-21−35,574→ 0 total→ Common Stock (10,725 underlying) - Purchase
Series B Preferred Stock
2020-08-07$2.81/sh+35,574$99,999→ 35,574 total→ Common Stock (10,725 underlying) - Conversion
Common Stock
2020-09-21+10,725→ 115,713 total - Award
Stock Option (right to buy)
2020-07-31+11,156→ 11,156 totalExercise: $5.54Exp: 2030-07-30→ Common Stock (11,156 underlying) - Award
Stock Option (right to buy)
2020-07-31+14,444→ 14,444 totalExercise: $5.54Exp: 2030-07-30→ Common Stock (14,444 underlying)
Footnotes (4)
- [F1]On September 21, 2020, the Series B Preferred Stock automatically converted into Common Stock on a 3.3169-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
- [F2]The option was granted on July 31, 2020. The shares underlying the option are scheduled to vest over four years in equal quarterly installments through July 31, 2024.
- [F3]The option was granted on July 31, 2020. The shares underlying the option are scheduled to vest over four years in equal quarterly installments through July 31, 2024.
- [F4]The Series B Preferred Stock was convertible into common stock on a 3.3169-for-one basis into the number of shares of common stock shown in Column 7 without payment of further consideration at the holder's election or upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.
Documents
Issuer
Dyne Therapeutics, Inc.
CIK 0001818794
Entity typeother
Related Parties
1- filerCIK 0001702233
Filing Metadata
- Form type
- 4
- Filed
- Sep 22, 8:00 PM ET
- Accepted
- Sep 23, 7:03 PM ET
- Size
- 14.2 KB